Comparing two blood thinners after stenting for high-risk patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests switching from a standard blood thinner (clopidogrel) to a lower dose of a stronger one (prasugrel) in people who have had a stent placed and are at high risk for both bleeding and heart problems. The goal is to see if the switch better prevents clots while keeping bleeding risks low.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stent placed in a heart artery (PCI) and are at high risk for bleeding.
- You have been taking low-dose aspirin and clopidogrel (Plavix) daily for at least 30 days after your stent.
- You are 18 years or older.
- You have not had a previous stroke or transient ischemic attack (TIA).
- You are not taking any other blood thinners (like warfarin, dabigatran, rivaroxaban, etc.) or daily heparin injections for a blood clot.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways to manage blood thinners after a stent. It tests whether switching from stronger drugs (prasugrel or ticagrelor) to clopidogrel is safe and effective for long-term heart protection.
This trial tests if a lower dose of prasugrel, taken alone (without aspirin), is safe and works well for people who have had a stent placed for chest pain or a heart attack. It might be an option for those who need to simplify their medication routine.
This trial tests if a very short course of dual antiplatelet therapy (two blood thinners) after getting a stent is safe and effective for patients aged 65 and older. The goal is to reduce bleeding risks while still preventing heart attacks.
This trial is testing whether lowering the dose of your current blood thinner or switching to a different one (clopidogrel) is safer and works just as well after you've had a stent placed. It's designed for people who are already on two blood thinners and are doing well.
This trial studies ways to reduce bleeding in people after a stent procedure (PCI) who have been taking two anti-platelet medicines (aspirin plus prasugrel or ticagrelor) for a set amount of time. It may help find a safer plan for preventing blood clots while lowering bleeding risk.
This trial tests if people who have been on two blood thinners (aspirin plus prasugrel or ticagrelor) for at least 90 days after getting a heart stent can safely switch to just one of those blood thinners. It aims to see if taking only one pill is as safe and effective as taking two.
Hear when a new Coronary Arterial Disease (CAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.